Tazemetostat - Epizyme

Drug Profile

Tazemetostat - Epizyme

Alternative Names: E-7438; EPZ-6438

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech; National Cancer Institute (USA)
  • Class Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdoid tumour; Mesothelioma; Follicular lymphoma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Histiocytosis; Mesothelioma; Non-Hodgkin's lymphoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Phase I B cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 10 Dec 2017 Tazemetostat - Epizyme receives Orphan Drug status for Follicular lymphoma in USA
  • 30 Nov 2017 National Cancer Institute plans a phase II trial for Ovarian cancer and Peritoneal cancer (Recurrent, Second-line therapy or greater) in USA in June 2018 (NCT03348631)
  • 01 Nov 2017 Tazemetostat - Epizyme receives Orphan Drug status for Mesothelioma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top